亚砷酸注射液对大肠癌患者无进展生存期及相关细胞因子的影响

Effects of arsenic trioxide on progression-free survival time and related cytokines in colorectal cancer patients

[目的]探讨亚砷酸注射液对大肠癌术后化疗后患者无进展生存期及相关细胞因子的影响。[方法]将64例大肠癌术后化疗后患者分为对照组和观察组,每组各32例。对照组为定期复查患者,观察组应用亚砷酸注射液间断巩固治疗。于疗程结束后记录患者无进展生存期(progression-free survival,PFS)和生存率,及体内相关细胞因子血清基质金属蛋白酶2(MMP-2)、基质金属蛋白酶9(MMP-9)、肿瘤坏死因子-α(TNF-α)及血管内皮生长因子(VEGF)的表达水平。[结果]观察组PFS(20.4±2.9)个月显著长于对照组(12.3±2.1)个月(P<0.05);观察组生存率为85.27%显著高于对照组的61.74%(P <0.05);观察组血清相关细胞因子(MMP-2、MMP-9、TNF-α、VEGF)表达水平显著低于对照组(P<0.05)。[结论]应用亚砷酸注射液间断巩固治疗可以显著抑制体内肿瘤相关细胞因子指标表达,减低肿瘤复发可能,延长大肠癌患者无进展生存期并提高生存率。

[Objective]To investigate the effect of arsenic trioxide on progression-free survival time and related cytokines in post-operation colorectal cancer patients after chemotherapy.[Methods]64cases of colorectal cancer patients were divided into control group and observation group,with 32 cases in each group.The control group patients received review regularly,observation group was treated with arsenic trioxide intermittently for consolidation treatment.PFS,survival rate and cytokines including MMP-2,MMP-9,TNF-α,VEGF were recorded after treatment.[Results]The PFS of the observation group(20.4±2.9)was significantly longer than that of the control group(12.3±2.1)(P<0.05).The survival rate of the observation group(85.27%)was significantly higher than that of the control group(61.74%)(P<0.05).The level of cytokines in observation group was significantly lower than that of the control group(P<0.05).[Conclusion]the intermittent application of arsenic trioxide in consolidation treatment of colorectal cancer patients could inhibit the expression of cancer-associated cytokines,reduce cancer recurrence,prolong the PFS and improve survival rate.